A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

This study tests a drug called satralizumab in children aged 2–11 with neuromyelitis optica spectrum disorder (NMOSD) — a rare disease where the immune system attacks the optic nerves and spinal cord, causing vision loss and paralysis. The study looks at how the drug behaves in children's bodies and whether it prevents attacks. You may be eligible if: - Your child is 2–11 years old and weighs at least 10 kg - Your child has been diagnosed with AQP4 antibody-positive NMOSD - Your child has had at least one documented attack in the past year - Your child has been neurologically stable for at least 30 days before the study You may NOT be eligible if: - Your child is pregnant or breastfeeding - Your child has another demyelinating disease that looks like NMOSD - Your child has an active or recurring serious infection - Your child has untreated tuberculosis - Your child received a live vaccine within 6 weeks before the study - Your child has a history of severe allergic reaction to a biologic drug Talk to your doctor to see if this trial is right for you.